Cystatin C: A prognostic marker after myocardial infarction in patients without chronic kidney disease

Abid, Leïla; Charfeddine, S.; Kammoun, S.; Turki, Mouna; Ayedi, Fatma

doi:10.1016/j.jsha.2015.10.001

Cited by 9 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our concern study has shown that group with a high Cystatin C level is associated with significant in hospital mortality (P value 0.025), and also it is going with Leila Abid et al, 24 Which showed (P value 0.01 clinically significant). And another study where Cystatin C was used as a prognostic biomarker in STEMI and Shlipak et al 25 Eriksson et al have asserted that an increase in cholesterol or LDL-cholesterol levels are considered as risk factors of IHD, but CYS-C may reflect precisely the presence or absence of CAD.…”

Section: Discussionsupporting

confidence: 68%

Prognostic value of cystatin C in acute coronary syndrome

Shuaila¹,

Abdulamir²,

Alshok³

2016

jcms

View full text Add to dashboard Cite

Objective Coronary artery disease associated with an increment with a variety of markers, one of them Cystatin C, in this study we evaluate its role in a prospective study as prognostic marker, and evaluate the correlation between Cystatin C plasma level and variety of acute coronary syndrome (ACS) complications. Methods A total 51 patients who admitted for Merjan Teaching Hospital coronary care unit whom ACS was diagnosis was made depend on history, clinical examination and investigation, and then blood sample was taken to measure plasma level and follow up for 6 months of any new events including new ischemia, rehospitalization, electrical and mechanical complication. Results Patient who admitted with ACS with high level of cystatin C associated with more mortality (P value: 0.09) and more electrical complication (P value: 0.035) and more rehospitalization (P value: 0.01), but failed to show a correlation with mechanical complication. Conclusion Elevated level of Cystatin C in patient admitted to hospital with ACS associated with an increase in hospital mortality, electrical complication, and rehospitalization and lower ejection fraction than a patient with a normal Cystatin C level.

show abstract

Section: Discussionsupporting

confidence: 68%

Prognostic value of cystatin C in acute coronary syndrome

Shuaila¹,

Abdulamir²,

Alshok³

2016

jcms

View full text Add to dashboard Cite

show abstract

“… 6 In addition, cystatin C has been shown to be useful for prognostic stratification in patients with ACS. 7 …”

Section: Introductionmentioning

confidence: 99%

Association Between Increased Levels of Cystatin C and the Development of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis

Einwoegerer¹,

Domingueti²

2018

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

BackgroundCystatin C seems promising for evaluating the risk of cardiovascular events and mortality.ObjectiveTo evaluate the association between high levels of cystatin C and the development of cardiovascular events or mortality.MethodsThe articles were selected in the Medline/PubMed, Web of Science, and Scielo databases. The eligibility criteria were prospective cohort observational trials that assessed the association of high serum levels of cystatin C with the development of cardiovascular events or mortality in individuals with normal renal function. Only studies that evaluated the mortality outcome compared the fourth with the first quartile of cystatin C and performed multivariate Cox’s proportional hazard regression analysis were included in the meta-analysis. A p value < 0,05 was considered significant.ResultsAmong the 647 articles found, 12 were included in the systematic review and two in the meta-analysis. The risk of development of adverse outcomes was assessed by eight studies using the hazard ratio. Among them, six studies found an increased risk of cardiovascular events or mortality. The multivariate regression analysis was performed by six studies, and the risk of developing adverse outcomes remained significant after the analysis in four of these studies. The result of the meta-analysis [HR = 2.28 (1.70-3.05), p < 0.001] indicated that there is a significant association between high levels of cystatin C and the risk of mortality in individuals with normal renal function.ConclusionThere is a significant association between high levels of cystatin C and the development of cardiovascular events or mortality in individuals with normal renal function.

show abstract

“…Some serum markers of renal function filtered by the renal glomerulus such as beta-2 microglobulin (B2M) and cystatin C are thought to be more sensitive parameters for renal function assessment and stronger predictors for death and cardiovascular events compared to serum creatinine (SCr). [ 3 4 ] B2M is a polypeptide which is present on the surface of nucleated human cells and thrombocytes. [ 5 ] It has been viewed as a useful parameter for estimated glomerular filtration rate (eGFR) and detecting mild-to-moderate renal insufficiency.…”

Section: Introductionmentioning

confidence: 99%

The prognostic values of beta-2 microglobulin for risks of cardiovascular events and mortality in the elderly patients with isolated systolic hypertension

Wang

Shi

et al. 2018

J Res Med Sci

View full text Add to dashboard Cite

Background:The present study aimed to investigate the effects of serum beta-2 microglobulin (B2M) on the risks of major cardiovascular events (MACEs) and all-cause death in Chinese elderly isolated systolic hypertension (ISH) patients without severe renal insufficiency (estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2).Materials and Methods:Serum B2M concentration, creatinine-eGFR, and blood pressure variability were evaluated in 460 elderly patients (mean age, 82.6 years; 28 women) with ISH in this observational study. The Cox proportional hazard model was adopted to calculate adjusted hazard ratios (HRs) of risk factors for cardiovascular events and all-cause deaths.Results:During a median follow-up period of 37.6 months, 63 patients (13.7%) died, and 65 patients (14.1%) had MACEs. Multivariable analysis showed that the higher serum B2M concentration (B2M ≥0.28 mg/dl) was an independent predictor of increased risk of MACEs (nonfatal acute myocardial infarction, acute heart failure, ischemic stroke, and cardiovascular deaths) and all-cause death (HR: 2.62, 95% confidence interval [CI]: 1.46–4.69, P = 0.001 and HR: 3.40, 95% CI: 1.78–6.48, P < 0.001, respectively) adjusting for other multiple confounders including creatinine-eGFR and cystatin C. In addition, blood pressure variability derived from ambulatory blood pressure measurement was not associated with incidence of MACEs and all-cause mortality (P > 0.05).Conclusion:Our data suggest that serum B2M concentration may be individually associated with MACEs and all-cause death in elderly ISH patients without severe renal insufficiency even after adjusted for creatinine-eGFR and cystatin C.

show abstract

Cystatin C: A prognostic marker after myocardial infarction in patients without chronic kidney disease

Cited by 9 publications

References 23 publications

Prognostic value of cystatin C in acute coronary syndrome

Prognostic value of cystatin C in acute coronary syndrome

Association Between Increased Levels of Cystatin C and the Development of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis

The prognostic values of beta-2 microglobulin for risks of cardiovascular events and mortality in the elderly patients with isolated systolic hypertension

Contact Info

Product

Resources

About